August 11, 2020
Masaaki Miyakawa, Executive Board Member in Charge of Pharma Affairs, Japan Medical Association Japan should tighten its drug reviews under the sakigake designation pathway and conditional early approval scheme, which will be revamped with solid legal backing in September under...read more